Skip to main content
Erschienen in: Diabetologia 5/2006

01.05.2006 | Article

The threshold for diagnosing impaired fasting glucose: a position statement by the European Diabetes Epidemiology Group

verfasst von: N. G. Forouhi, B. Balkau, K. Borch-Johnsen, J. Dekker, C. Glumer, Q. Qiao, A. Spijkerman, R. Stolk, A. Tabac, N. J. Wareham, On behalf of EDEG

Erschienen in: Diabetologia | Ausgabe 5/2006

Einloggen, um Zugang zu erhalten

Abstract

The category of IFG was introduced in the late 1990s to denote a state of non-diabetic hyperglycaemia defined by a fasting plasma glucose (FPG) concentration between 6.1 and 6.9 mmol/l. In 2003 the American Diabetes Association recommended that this diagnostic threshold be lowered to 5.6 mmol/l. The justification for lowering the threshold has been questioned. This simple change in cut-off value creates a pandemic of IFG, with a two- to five-fold increase in the prevalence of IFG across the world. Such a change in threshold has far-reaching public health implications. The European Diabetes Epidemiology Group (EDEG) has reviewed the evidence for this lower cut-off point for the definition of IFG and concludes that the previous definition should not be altered. EDEG further recommends that the value of all categorical definitions of non-diabetic hyperglycaemia should be reconsidered.
Literatur
1.
Zurück zum Zitat Genuth S, Alberti KG, Bennett P et al (2003) Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26:3160–3167 Genuth S, Alberti KG, Bennett P et al (2003) Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26:3160–3167
2.
Zurück zum Zitat de Vegt F, Dekker JM, Jager A et al (2001) Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: the Hoorn Study. JAMA 285:2109–2113 de Vegt F, Dekker JM, Jager A et al (2001) Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: the Hoorn Study. JAMA 285:2109–2113
3.
Zurück zum Zitat Shaw JE, Zimmet PZ, de Court et al (1999) Impaired fasting glucose or impaired glucose tolerance. What best predicts future diabetes in Mauritius? Diabetes Care 22:399–402 Shaw JE, Zimmet PZ, de Court et al (1999) Impaired fasting glucose or impaired glucose tolerance. What best predicts future diabetes in Mauritius? Diabetes Care 22:399–402
4.
Zurück zum Zitat Balkau B, Hillier T, Vierron E et al (2005) Comment to: Borch-Johnsen K, Colagiuri S, Balkau B et al (2004) Creating a pandemic of prediabetes: the proposed new diagnostic criteria for impaired fasting glycaemia. Diabetologia 47:1396-1402. Diabetologia 48:801–802 Balkau B, Hillier T, Vierron E et al (2005) Comment to: Borch-Johnsen K, Colagiuri S, Balkau B et al (2004) Creating a pandemic of prediabetes: the proposed new diagnostic criteria for impaired fasting glycaemia. Diabetologia 47:1396-1402. Diabetologia 48:801–802
5.
Zurück zum Zitat Cicero AF, Dormi A, Nascetti S et al (2005) Relative role of major risk factors for type 2 diabetes development in the historical cohort of the Brisighella Heart Study: an 8-year follow-up. Diabet Med 22:1263–1266 Cicero AF, Dormi A, Nascetti S et al (2005) Relative role of major risk factors for type 2 diabetes development in the historical cohort of the Brisighella Heart Study: an 8-year follow-up. Diabet Med 22:1263–1266
6.
Zurück zum Zitat Shaw JE, Zimmet PZ, Hodge AM et al (2000) Impaired fasting glucose: how low should it go? Diabetes Care 23:34–39 Shaw JE, Zimmet PZ, Hodge AM et al (2000) Impaired fasting glucose: how low should it go? Diabetes Care 23:34–39
7.
Zurück zum Zitat Gabir MM, Hanson RL, Dabelea D et al (2000) The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diabetes Care 23:1108–1112 Gabir MM, Hanson RL, Dabelea D et al (2000) The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diabetes Care 23:1108–1112
8.
Zurück zum Zitat Tirosh A, Shai I, Tekes-Manova D et al (2005) Normal fasting plasma glucose levels and type 2 diabetes in young men. N Engl J Med 353:1454–1462 Tirosh A, Shai I, Tekes-Manova D et al (2005) Normal fasting plasma glucose levels and type 2 diabetes in young men. N Engl J Med 353:1454–1462
9.
Zurück zum Zitat The DECODE Study Group (2003) Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 26:688–696 The DECODE Study Group (2003) Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 26:688–696
10.
Zurück zum Zitat Wen CP, Cheng TY, Tsai SP et al (2005) Increased mortality risks of pre-diabetes (impaired fasting glucose) in Taiwan. Diabetes Care 28:2756–2761 Wen CP, Cheng TY, Tsai SP et al (2005) Increased mortality risks of pre-diabetes (impaired fasting glucose) in Taiwan. Diabetes Care 28:2756–2761
11.
Zurück zum Zitat Lawes CM, Parag V, Bennett DA et al (2004) Blood glucose and risk of cardiovascular disease in the Asia Pacific region. Diabetes Care 27:2836–2842 Lawes CM, Parag V, Bennett DA et al (2004) Blood glucose and risk of cardiovascular disease in the Asia Pacific region. Diabetes Care 27:2836–2842
12.
Zurück zum Zitat Levitan EB, Song Y, Ford ES et al (2004) Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med 164:2147–2155 Levitan EB, Song Y, Ford ES et al (2004) Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med 164:2147–2155
13.
Zurück zum Zitat Sorkin JD, Muller DC, Fleg JL et al (2005) The relation of fasting and 2 h postchallenge plasma glucose concentrations to mortality: data from the Baltimore Longitudinal Study of Aging with a critical review of the literature. Diabetes Care 28:2626–2632 Sorkin JD, Muller DC, Fleg JL et al (2005) The relation of fasting and 2 h postchallenge plasma glucose concentrations to mortality: data from the Baltimore Longitudinal Study of Aging with a critical review of the literature. Diabetes Care 28:2626–2632
14.
Zurück zum Zitat de Vegt F, Dekker JM, Ruhe HG et al (1999) Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 42:926–931 de Vegt F, Dekker JM, Ruhe HG et al (1999) Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 42:926–931
15.
Zurück zum Zitat Kanaya AM, Herrington D, Vittinghoff E et al (2005) Impaired fasting glucose and cardiovascular outcomes in postmenopausal women with coronary artery disease. Ann Intern Med 142:813–820 Kanaya AM, Herrington D, Vittinghoff E et al (2005) Impaired fasting glucose and cardiovascular outcomes in postmenopausal women with coronary artery disease. Ann Intern Med 142:813–820
16.
Zurück zum Zitat Hanefeld M, Temelkova-Kurktschiev T, Schaper F et al (1999) Impaired fasting glucose is not a risk factor for atherosclerosis. Diabet Med 16:212–218 Hanefeld M, Temelkova-Kurktschiev T, Schaper F et al (1999) Impaired fasting glucose is not a risk factor for atherosclerosis. Diabet Med 16:212–218
17.
Zurück zum Zitat Hanefeld M, Koehler C, Henkel E et al (2000) Post-challenge hyperglycaemia relates more strongly than fasting hyperglycaemia with carotid intima-media thickness: the RIAD Study. Risk factors in impaired glucose tolerance for atherosclerosis and diabetes. Diabet Med 17:835–840 Hanefeld M, Koehler C, Henkel E et al (2000) Post-challenge hyperglycaemia relates more strongly than fasting hyperglycaemia with carotid intima-media thickness: the RIAD Study. Risk factors in impaired glucose tolerance for atherosclerosis and diabetes. Diabet Med 17:835–840
18.
Zurück zum Zitat Blake DR, Meigs JB, Muller DC et al (2004) Impaired glucose tolerance, but not impaired fasting glucose, is associated with increased levels of coronary heart disease risk factors: results from the Baltimore Longitudinal Study on aging. Diabetes 53:2095–2100 Blake DR, Meigs JB, Muller DC et al (2004) Impaired glucose tolerance, but not impaired fasting glucose, is associated with increased levels of coronary heart disease risk factors: results from the Baltimore Longitudinal Study on aging. Diabetes 53:2095–2100
19.
Zurück zum Zitat Vaccaro O, Riccardi G (2005) Changing the definition of impaired fasting glucose: impact on the classification of individuals and risk definition. Diabetes Care 28:1786–1788 Vaccaro O, Riccardi G (2005) Changing the definition of impaired fasting glucose: impact on the classification of individuals and risk definition. Diabetes Care 28:1786–1788
20.
Zurück zum Zitat Tuomilehto J, Lindstrom J, Eriksson JG et al (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343–1350 Tuomilehto J, Lindstrom J, Eriksson JG et al (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343–1350
21.
Zurück zum Zitat Knowler WC, Barrett-Connor E, Fowler SE et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403 Knowler WC, Barrett-Connor E, Fowler SE et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403
22.
Zurück zum Zitat Pan XR, Li GW, Hu YH et al (1997) Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20:537–544 Pan XR, Li GW, Hu YH et al (1997) Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20:537–544
23.
Zurück zum Zitat Chiasson JL, Josse RG, Gomis R et al (2002) Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359:2072–2077 Chiasson JL, Josse RG, Gomis R et al (2002) Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359:2072–2077
24.
Zurück zum Zitat Chiasson JL, Josse RG, Gomis R et al (2003) Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290:486–494 Chiasson JL, Josse RG, Gomis R et al (2003) Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290:486–494
25.
Zurück zum Zitat Ratner R, Goldberg R, Haffner S et al (2005) Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care 28:888–894 Ratner R, Goldberg R, Haffner S et al (2005) Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care 28:888–894
26.
Zurück zum Zitat Dyson PA, Hammersley MS, Morris RJ et al (1997) The Fasting Hyperglycaemia Study: II. Randomized controlled trial of reinforced healthy-living advice in subjects with increased but not diabetic fasting plasma glucose. Metabolism 46:50–55 Dyson PA, Hammersley MS, Morris RJ et al (1997) The Fasting Hyperglycaemia Study: II. Randomized controlled trial of reinforced healthy-living advice in subjects with increased but not diabetic fasting plasma glucose. Metabolism 46:50–55
27.
Zurück zum Zitat Karunakaran S, Hammersley MS, Morris RJ et al (1997) The Fasting Hyperglycaemia Study: III. Randomized controlled trial of sulfonylurea therapy in subjects with increased but not diabetic fasting plasma glucose. Metabolism 46:56–60 Karunakaran S, Hammersley MS, Morris RJ et al (1997) The Fasting Hyperglycaemia Study: III. Randomized controlled trial of sulfonylurea therapy in subjects with increased but not diabetic fasting plasma glucose. Metabolism 46:56–60
28.
Zurück zum Zitat Davidson MB, Landsman PB, Alexander CM (2003) Lowering the criterion for impaired fasting glucose will not provide clinical benefit. Diabetes Care 26:3329–3330 Davidson MB, Landsman PB, Alexander CM (2003) Lowering the criterion for impaired fasting glucose will not provide clinical benefit. Diabetes Care 26:3329–3330
29.
Zurück zum Zitat Borch-Johnsen K, Colagiuri S, Balkau B et al (2004) Creating a pandemic of prediabetes: the proposed new diagnostic criteria for impaired fasting glycaemia. Diabetologia 47:1396–1402 Borch-Johnsen K, Colagiuri S, Balkau B et al (2004) Creating a pandemic of prediabetes: the proposed new diagnostic criteria for impaired fasting glycaemia. Diabetologia 47:1396–1402
30.
Zurück zum Zitat Tai ES, Goh SY, Lee JJ et al (2004) Lowering the criterion for impaired fasting glucose: impact on disease prevalence and associated risk of diabetes and ischemic heart disease. Diabetes Care 27:1728–1734 Tai ES, Goh SY, Lee JJ et al (2004) Lowering the criterion for impaired fasting glucose: impact on disease prevalence and associated risk of diabetes and ischemic heart disease. Diabetes Care 27:1728–1734
31.
Zurück zum Zitat Qiao Q, Lindstrom J, Valle TT et al (2003) Progression to clinically diagnosed and treated diabetes from impaired glucose tolerance and impaired fasting glycaemia. Diabet Med 20:1027–1033 Qiao Q, Lindstrom J, Valle TT et al (2003) Progression to clinically diagnosed and treated diabetes from impaired glucose tolerance and impaired fasting glycaemia. Diabet Med 20:1027–1033
32.
Zurück zum Zitat Wang JJ, Yuan SY, Zhu LX et al (2004) Effects of impaired fasting glucose and impaired glucose tolerance on predicting incident type 2 diabetes in a Chinese population with high post-prandial glucose. Diabetes Res Clin Pract 66:183–191 Wang JJ, Yuan SY, Zhu LX et al (2004) Effects of impaired fasting glucose and impaired glucose tolerance on predicting incident type 2 diabetes in a Chinese population with high post-prandial glucose. Diabetes Res Clin Pract 66:183–191
33.
Zurück zum Zitat Wareham NJ, Byrne CD, Williams R et al (1999) Fasting proinsulin concentrations predict the development of type 2 diabetes. Diabetes Care 22:262–270 Wareham NJ, Byrne CD, Williams R et al (1999) Fasting proinsulin concentrations predict the development of type 2 diabetes. Diabetes Care 22:262–270
Metadaten
Titel
The threshold for diagnosing impaired fasting glucose: a position statement by the European Diabetes Epidemiology Group
verfasst von
N. G. Forouhi
B. Balkau
K. Borch-Johnsen
J. Dekker
C. Glumer
Q. Qiao
A. Spijkerman
R. Stolk
A. Tabac
N. J. Wareham
On behalf of EDEG
Publikationsdatum
01.05.2006
Verlag
Springer-Verlag
Erschienen in
Diabetologia / Ausgabe 5/2006
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-006-0189-4

Weitere Artikel der Ausgabe 5/2006

Diabetologia 5/2006 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Neu im Fachgebiet Innere Medizin

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.